DK1385577T3 - Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi - Google Patents

Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Info

Publication number
DK1385577T3
DK1385577T3 DK02719751T DK02719751T DK1385577T3 DK 1385577 T3 DK1385577 T3 DK 1385577T3 DK 02719751 T DK02719751 T DK 02719751T DK 02719751 T DK02719751 T DK 02719751T DK 1385577 T3 DK1385577 T3 DK 1385577T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
against benign
Prior art date
Application number
DK02719751T
Other languages
Danish (da)
English (en)
Inventor
Susanne Buser
Anthony P D W Ford
Barbara Lenz
Andrew John Sleight
Pierre Vankan
Torsten Hoffmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1385577T3 publication Critical patent/DK1385577T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02719751T 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi DK1385577T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
DK1385577T3 true DK1385577T3 (da) 2006-08-21

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719751T DK1385577T3 (da) 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Country Status (17)

Country Link
US (1) US20030004157A1 (es)
EP (1) EP1385577B1 (es)
JP (1) JP4146730B2 (es)
KR (1) KR100599134B1 (es)
CN (1) CN100398106C (es)
AR (1) AR035935A1 (es)
AT (1) ATE323531T1 (es)
AU (1) AU2002250876B2 (es)
BR (1) BR0209151A (es)
CA (1) CA2444395C (es)
DE (1) DE60210760T2 (es)
DK (1) DK1385577T3 (es)
ES (1) ES2261657T3 (es)
MX (1) MXPA03009720A (es)
PT (1) PT1385577E (es)
WO (1) WO2002085458A2 (es)
ZA (1) ZA200308110B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
RU2330022C2 (ru) * 2003-01-31 2008-07-27 Ф.Хоффманн-Ля Рош Аг НОВАЯ КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ 2-(3, 5-БИС-ТРИФТОРМЕТИЛФЕНИЛ)-N-[6-(1, 1-ДИОКСО-1 λ6-ТИОМОРФОЛИН-4-ИЛ)-4-(4-ФТОР-2-МЕТИЛФЕНИЛ)ПИРИДИН-3-ИЛ]-N-МЕТИЛИЗОБУТИРАМИДА
EP1643998B1 (en) * 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
EP3208272B1 (en) 2005-11-08 2020-01-08 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
EA201070700A1 (ru) 2007-12-07 2011-06-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения циклоалкилкарбоксамидопиридинбензойных кислот
RS55559B1 (sr) 2007-12-07 2017-05-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
RU2011141794A (ru) 2009-03-17 2013-04-27 Дайити Санкио Компани, Лимитед Амидное производное
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
CN105745198B (zh) 2013-11-08 2018-09-21 橘生药品工业株式会社 羧甲基哌啶衍生物
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
CN111741755B (zh) * 2018-02-02 2024-04-16 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 肠胃外制剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
HUP0002929A3 (en) * 1997-08-06 2002-01-28 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
WO1999007681A1 (en) * 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
PT1394150E (pt) * 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
SI1303490T1 (sl) * 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
JP4146730B2 (ja) 2008-09-10
KR100599134B1 (ko) 2006-07-12
ES2261657T3 (es) 2006-11-16
WO2002085458A3 (en) 2003-10-30
CA2444395C (en) 2010-12-21
US20030004157A1 (en) 2003-01-02
CN1503684A (zh) 2004-06-09
WO2002085458A2 (en) 2002-10-31
EP1385577A2 (en) 2004-02-04
DE60210760T2 (de) 2006-11-23
CN100398106C (zh) 2008-07-02
KR20040007503A (ko) 2004-01-24
MXPA03009720A (es) 2004-01-29
PT1385577E (pt) 2006-08-31
ZA200308110B (en) 2005-03-30
EP1385577B1 (en) 2006-04-19
BR0209151A (pt) 2004-07-13
ATE323531T1 (de) 2006-05-15
CA2444395A1 (en) 2002-10-31
JP2004529931A (ja) 2004-09-30
DE60210760D1 (de) 2006-05-24
AU2002250876B2 (en) 2005-03-03
AR035935A1 (es) 2004-07-28

Similar Documents

Publication Publication Date Title
DK1385577T3 (da) Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi
DK1278350T3 (da) Autentificering af verificering for mobilbrugere
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
PT1208104E (pt) Inibidores triciclicos de polimerases de poli(adp-ribose)
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DK1307181T3 (da) Hidtil ukendte sammensætninger af minoxidil
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20053783D0 (no) Behandling av godartet prostatahyperplasi
DE60120419D1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
DK1438306T3 (da) Derivater af UK-2A
LV12770B (lv) Poli(adp-ribozo) polimerazu tricikliskie inhibitori
DK1505998T3 (da) Forbedret anvendelse af hop-syrer som antimikrobielle midler
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
DE60212156D1 (de) Reibungsdämpfendes bein
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1354027T3 (da) Stabilisering af drikkevarer
ATE374183T1 (de) Nk1-antagonisten
NO20041968L (no) Anvendelse av cystationin
DK1276721T3 (da) Methylering af indolforbindelser under anvendelse af dimethylcarbonat
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
IS7251A (is) Inndælingarlausn sem samanstendur af LHRH mótlyfi
DK1408964T3 (da) Hidtil ukendt anvendelse af 2-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman og fysiologisk acceptable salte deraf
NO20023785L (no) Vanndispergerbar formulering av paroxetin
DK1268482T3 (da) Pyranoindoler til behandling af glaukom